Somatostatin: an endogenous antiepileptic.
Mol Cell Endocrinol
; 286(1-2): 96-103, 2008 May 14.
Article
em En
| MEDLINE
| ID: mdl-18221832
ABSTRACT
The neuropeptide somatostatin (SST) is highly expressed in brain regions associated with seizures. In hippocampus, SST expression and release is regulated by seizures, and SST-containing neurons within the hilus of the dentate gyrus are sensitive to seizure-induced death. In vivo and in vitro studies suggest that the loss of SST function in the dentate could contribute to epileptogenesis and seizure susceptibility. SST also has inhibitory actions in the CA1 and CA3 hippocampus indicating this peptide is an important homeostatic regulator throughout the hippocampus. In vivo studies show SST has robust antiepileptic properties with the major site of action being hippocampus. In rodents, somatostatin receptor subtype 2 (SST(2)) and SST(4) appear to mediate the majority of the antiepileptic actions of SST, with SST(2) predominate in rat and SST(4) in mouse. Thus SST receptors may be appropriate targets for new antiepileptic drugs (AEDs), although validation in human tissue is lacking.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Somatostatina
/
Receptores de Somatostatina
/
Epilepsia
/
Hipocampo
/
Anticonvulsivantes
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Mol Cell Endocrinol
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Estados Unidos